{"id":"eth47","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ETH47 works by binding to the SARS-CoV-2 main protease, thereby inhibiting viral replication. This mechanism of action is crucial for the treatment of COVID-19. ETH47 has shown promise in preclinical studies, but further research is needed to confirm its efficacy and safety.","oneSentence":"ETH47 is a small molecule that targets the SARS-CoV-2 main protease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:52:11.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT07059767","phase":"PHASE2","title":"Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge","status":"RECRUITING","sponsor":"Ethris GmbH","startDate":"2025-06-24","conditions":"Asthma (Diagnosis)","enrollment":50},{"nctId":"NCT07055321","phase":"PHASE1","title":"A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants","status":"COMPLETED","sponsor":"Ethris GmbH","startDate":"2023-11-29","conditions":"Healthy Subjects","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ETH47","genericName":"ETH47","companyName":"Ethris GmbH","companyId":"ethris-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ETH47 is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}